Online inquiry

IVTScrip™ mRNA-Anti-TPBG, ABR-217620(Cap 0, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ1229MR)

This product GTTS-WQ1229MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets TPBG gene. The antibody can be applied in Renal Cell Carcinoma (RCC), Non-small lung carcinoma research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Mus musculus
RefSeq NM_001166392.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7162
UniProt ID Q13641
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TPBG, ABR-217620(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ1229MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ953MR IVTScrip™ mRNA-Anti-CD40, ABBV-323(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ABBV-323
GTTS-WQ4580MR IVTScrip™ mRNA-Anti-CD40LG, BMS-986004(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BMS-986004
GTTS-WQ10130MR IVTScrip™ mRNA-Anti-LAG3, LAG-525(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA LAG-525
GTTS-WQ12443MR IVTScrip™ mRNA-Anti-IL2RB, NKTR-214(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA NKTR-214
GTTS-WQ15201MR IVTScrip™ mRNA-Anti-TNF, TA-650(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA TA-650
GTTS-WQ2354MR IVTScrip™ mRNA-Anti-MS4A1, AME-133v(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA AME-133v
GTTS-WQ5304MR IVTScrip™ mRNA-Anti-ALCAM, CD166 AADC(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA CD166 AADC
GTTS-WQ14555MR IVTScrip™ mRNA-Anti-CD19, aCD1919(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA aCD1919
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW